Managing scleromyxedema with intravenous immunoglobulin: Acute worsening of scleromyxedema with biclonal gammopathy

Acta Dermatovenerologica Alpina, Pannonica et Adriatica

Volumn 19, Issue 4, 2010, Pages 15-19

  Manousaridis, Ioannis ^a   Loeser, Christoph ^b   Goerdt, Sergij ^a   Hassel, Jessica C ^c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Clinical Centre of the City of Ludwigshafen   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Intravenous immunoglobulin; Scleromyxedema

Indexed keywords

CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; METHYLPREDNISOLONE;

ADULT; ARTICLE; BICLONAL IMMUNOGLOBULINEMIA; CASE REPORT; DISEASE ASSOCIATION; DRUG WITHDRAWAL; GAMMOPATHY; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; MALE; MULTIPLE CYCLE TREATMENT; PHOTOTHERAPY; QUALITY OF LIFE; SCLEROMYXEDEMA; SKINFOLD THICKNESS; ULTRAVIOLET A RADIATION;

HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PARAPROTEINEMIAS; SCLEROMYXEDEMA; SKIN;

EID: 79953785634     PISSN: 13184458     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Rongioletti F, Rebora A. Mucinoses. In: Bolognia JL, Jorizzo JL (editors). Dermatology e-dition, 2nd Edition.
2. Pomann JJ, Rudner EJ. Scleromyxedema revisited. Int J Dermatol. 2003 Jan;42(1):31-5. (Pubitemid 41709816)
3. Heymann WR. Scleromyxedema. J Am Acad Dermatol. 2007 Nov;57(5):890-1.
4. Desai AD, James WD. Lichen myxedematosus. In: Lebwohl MG, Heymann WR, Berth-Jones J, Coulson IC, editors. Treatment of skin disease: comprehensive therapeutic strategies. 2nd ed. London (UK): Elsevier; 2006. p. 343-4.
5. Enk A, Fierlbeck G, French L, et al. Use of high-dose immunoglobulins in dermatology. J Dtsch Dermatol Ges. 2009 Sep;7(9):806-12.
6. Lister RK, Jolles S, Whittaker S, et al. Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg). J Am Acad Dermatol. 2000 Aug;43(2 Pt 2):403-8. (Pubitemid 30636551)
7. Wojas-Pelc A, Błaszczyk M, Glińska M, et al. Tumorous variant of scleromyxedema. Successful therapy with intravenous immunoglobulins. J Eur Acad Dermatol Venereol. 2005 Jul;19(4):462-5. (Pubitemid 40946101)
8. Majeski C, Taher M, Grewal P, et al. Combination oral prednisone and intravenous immunoglobulin in the treatment of scleromyxedema. J Cutan Med Surg. 2005 Jun;9(3):99-104.
9. Gholam P, Hartmann M, Enk A. Arndt-Gottron scleromyxoedema: successful therapy with intravenous immunoglobulins. Br J Dermatol. 2007 Nov;157(5):1058-60. (Pubitemid 47583517)
10. Blum M, Wigley FM, Hummers LK. Scleromyxedema: a case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG). Medicine (Baltimore). 2008 Jan;87(1):10-20.
11. Efthimiou P, Blanco M. Intravenous gammaglobulin and thalidomide may be an effective therapeutic combination in refractory scleromyxedema: case report and discussion of the literature. Semin Arthritis Rheum. 2008 Dec;38(3):188-94.
12. Binitha MP, Nandakumar G, Thomas D. Suspected cardiac toxicity to intravenous immunoglobulin used for treatment of scleromyxedema. Indian J Dermatol Venereol Leprol. 2008 May-Jun;74(3):248-50. (Pubitemid 351918881)
13. Rey JB, Luria RB. Treatment of scleromyxedema and the dermatoneuro syndrome with intravenous immunoglobulin. J Am Acad Dermatol. 2009 Jun;60(6):1037-41.
14. Körber A, Franckson T, Grabbe S, et al. Successful therapy of scleromyxoedema Arndt-Gottron with low-dose intravenous immunoglobulin. J Eur Acad Dermatol Venereol. 2007 Apr;21(4):553-4. (Pubitemid 46454922)
15. Lopez L, Wierzbicka-Hainaut E, Villers A, et al. Efficacy of intravenous immunoglobulin in Arndt-Gottron scleromyxedema. Ann Dermatol Venereol. 2009 Apr;136(4):330-6.